Membership: Join my YouTube channel membership and unlock exclusive perks! As a member, you'll get early access to videos to stay ahead with the latest content before anyone else. Investor tier members get access to my spreadsheets, and VIP discord members get access to our private discord community
1 extracted signal · 1 resolved · 0 still active
Parkev Tatevosian, CFAIndependent analyst profile- Source published
- 30 Aug 2025, 01:20 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC

AI-generated source summary
The analysis predicts UnitedHealth's stock price may reach between $400 and $430 by the end of 2026, presenting this as a likely scenario, starting from a current price around $304. The analysis utilizes earnings per share estimates for 2027, retrieved from fiscal.ai ($21.74) to project stock prices, combined with different forward price-to-earnings ratios. If the forward PE remains constant at 18.92, the stock may end next year at $411.32. Increasing the forward PE ratio to 20 could push the stock to $434.80, to 22 could push the stock to $478.28 and to 25 could push the stock to $543.50. UnitedHealth is a health care company with less risk.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
Parkev Tatevosian, CFA
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.
